Abiraterone appeal: one step closer to getting life-extending hormone treatment to men who can’t have chemotherapy.
The National Institute for Health and Care Excellence (NICE) uphold our appeal against their refusal to make abiraterone available for men newly diagnosed with high-risk advanced prostate cancer.
Read more